Product Name | LFM A13 |
Description |
BTK kinase inhibitor |
Purity | >97% (TLC) |
CAS No. | 62004-35-7 |
Molecular Formula | C11H8Br2N2O2 |
Molecular Weight | 360.0 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml) |
Source | Synthetic |
Appearance | Yellow solid |
SMILES | C/C(=C(C#N)/C(=O)NC1=C(C=CC(=C1)Br)Br)/O |
InChI | InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17) |
InChIKey | UVSVTDVJQAJIFG-UHFFFAOYSA-N |
Safety Phrases |
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
Cite This Product | LFM A13 (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-461) |
Alternative Names | 2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 54686938 |
Scientific Background | LFM A13 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK). |
References | 1. Vassilev A., Ozer Z., Navara C., Mahajan S., & Uckun F.M. (1999). J. Biol. Chem. 274(3): 1646–1656. |
Reviews
There are no reviews yet.